Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Active, not recruitingOBSERVATIONAL
Enrollment

271

Participants

Timeline

Start Date

August 12, 2019

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Achondroplasia
Trial Locations (32)

5009

Haukeland Universitetssjukehus, Bergen

19803

Nemours Alfred I. Dupont Hospital for Children, Wilmington

20122

Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlino, Milan

21211

Johns Hopkins School of Medicine, Baltimore

24086

Hospital Universitario La Paz, Madrid

37232

Vanderbilt University Medical Center, Nashville

39120

Otto-von-Guericke-University Magdeburg Medical Fakulty, Magdeburg

45229

Cincinnati Children's Hospital, Cincinnati

53705

University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic, Madison

65211

University of Missouri, Columbia

80045

Children's Hospital Colorado, Aurora

94609

Benioff Children's Hospital Oakland, Oakland

229899

KK Women's and Children's Hospital, Singapore

Unknown

Hospital de Pediatría SAMIC Prof. Dr. Juan P. Garrahan, Buenos Aires

Murdoch Children's Research Institute, Parkville

Hopital Femme Mere Enfant, Lyon

Hopital Necker-Enfants Malades, Paris

Hopital des Enfants, Toulouse

Hospital Universitario Virgen de la Victoria, Málaga

Bristol Royal Hospital for Children, Bristol

Birmingham Children's Hospital, Birmingham

Queen Elizabeth University Hospital, Glasgow

St. Thomas' Hospital, London

Manchester University Children's Hospital, Manchester

Sheffield Children's Hospital, Sheffield

T6G 2H7

Stollery Children's Hospital, Edmonton

N6A 5W9

Children's Hospital - London Health Sciences Center, London

K1N 6N5

University of Ottawa, Ottawa

H3C 3J7

University of Montreal, Montreal

00168

Rare Disease Unit Fondazione Policlinico A Gemelli IRCCS, Rome

0372

Oslo Universitetssykehus, Oslo

08305

Vithas Hospital San Jose, Barcelona

All Listed Sponsors
lead

QED Therapeutics, Inc., a Bridgebio company

INDUSTRY